Case Report

Catastrophic Brain Aspergillosis after Liver Transplantation

Mohammadmahdi Abbasi, Shirin Shams Ardakani, Nasir Fakhar, Hamid Eshaghi, Hosein Alimadadi, Toktam Faghihi, Behdad Gharib, Meisam Sharifzadeh, and Masoomeh Safaei

1Department of Pediatrics, Children’s Medical Center, Tehran University of medical Sciences, Teran, Iran
2Division of Liver Transplantation, Imam Khomeini Hospital, TUMS, Teran, Iran
3Department of Pediatric Infectious Disease, Children’s Medical Center, TUMS, Teran, Iran
4Department of Pediatrics, Tehran University of medical Sciences, Teran, Iran
5Children’s Medical Center, Pediatrics Center of Excellence, Teran, Iran
6Pediatric gastroenterology Research Center, Tehran University of medical Sciences, Teran, Iran
7Department of Clinical Pharmacy, Children’s Medical Center, TUMS, Teran, Iran
8Division of Pediatric Critical Care, Children’s Medical Center, TUMS, Teran, Iran
9Pediatrician, Assistant professor of pediatric Intensive care, Division of pediatric critical care, Children medical center, Tehran University of medical science, Iran
10Department of pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran university of Medical Sienes, Teran, Iran

Correspondence should be addressed to Meisam Sharifzadeh; meisamsharifzadeh49@gmail.com

Received 6 December 2019; Revised 20 May 2020; Accepted 2 February 2021; Published 15 February 2021

Academic Editor: Piero Boraschi

Copyright © 2021 Mohammadmahdi Abbasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Liver transplantation has many complications. Because of receiving immunosuppressive regimens, infectious complications in these patients may have fatal results. Aspergillosis in solid organ recipients is one of the most common fungal infections that usually occur 1 month after transplantation. Aspergillus infection mainly involves the lungs. Although the central nervous system may get involved due to hematogenous spreading from lungs, isolated central nervous system involvement is rarely reported. Case Presentation. The patient was an 8-year-old boy, with a case of Wilson disease, who underwent liver transplantation due to acute fulminant hepatic failure. Four days after the surgery, he was affected by fever, agitation, loss of consciousness, hemiparesis, and focal seizure. Brain MRI showed abscess formation, whereas chest X-ray was normal. Intravenous antibiotics were initiated but the patient’s condition was not improving; therefore, surgical drainage of the abscess was performed. The pathological investigation was compatible with aspergillosis. Antifungal therapy with voriconazole was administrated. His symptoms were resolved but unfortunately, brain lesions caused persistent vegetative state. Discussion. Aspergillus is a ubiquitous organism that mainly occurs in immunocompromised patients. Aspergillosis could be prevented by environmental modification such as installing high-efficiency particulate air filters. Chemoprevention with triazoles, echinocandins, and polyenes is also effective. Voriconazole is the drug of choice for aspergillosis treatment. Although voriconazole is a highly effective antifungal drug, cerebral aspergillosis is often fatal.

1. Background

Liver transplantation has become a more successful way to manage end-stage liver disease over the past few decades. Therefore, the importance of being aware of its complications is an even greater concern for physicians all over the world. Liver transplantation for end-stage liver diseases in children is done from both living and cadaveric donors,
and the rate of transplantation from living donors is higher in children as its complications. Candidates for liver transplantation are divided into 5 groups:

1. Extrahepatic cholestasis
2. Intrahepatic cholestasis
3. Metabolic diseases
4. Acute liver failure
5. Others: primary liver tumor and cystic fibrosis

The complications of liver transplantation include vascular complication, hepatic artery stenosis, hepatic artery thrombosis, portal vein thrombosis, portal vein stenosis, IVC stenosis, IVC thrombosis, biliary complication, biliary obstruction, bile leak, bile duct stones, mucocele, organ rejection, localized fluid collection, posttransplantation lymphoproliferative disorders, and infectious complications.

The immunosuppressive therapies for pediatric transplantation include administration of corticosteroids, calcineurin inhibitors (cyclosporine and tacrolimus), mycophenolate mofetil, sirolimus, and IL2 receptor inhibitors [1, 2]. Infectious complication after transplantation surgery is one of the most frequent causes of total morbidity and mortality. Between all infections, 50-60% are bacterial, 20-40% are viral, 5-15% are fungal, and less than 10% are due to parasites [3–5]. Mortality rates of invasive fungal infection (IFI) have ranged between 25% and 69% in orthotopic liver transplantation recipients [3, 6–19]. Candida species are responsible for about 80% of all invasive fungal infections [3, 9–16]. Aspergillus species cause about 10% to 20% of all invasive fungal infections [4, 13–16, 20–24]. The reported incidence of aspergillosis after OLT varies between 1.5% and 4% in most studies [3, 19, 22]. Clinical manifestations of aspergillosis include invasive pulmonary aspergillosis, invasive aspergillus sinusitis, cutaneous aspergillosis, and cerebral aspergillosis [3–5, 7, 13, 16, 20–22]. Although CNS involvement is a common situation due to disseminated invasive aspergillosis, isolated CNS involvement is rarely reported.

2. Case Presentation

The patient was an 8-year-old boy, with a case of Wilson disease proved by liver biopsy (Figures 1 and 2), who underwent liver transplantation from a deceased donor. Pretransplant screenings for donor and recipient such as HIV, HBV, HCV, HDV, CMV, EBV, and syphilis for donor and HIV, HAV, HBV, HCV, HDV, CMV, EBV, VZV, PPD, IGRA, and syphilis for the recipient were negative. After the surgery,
the patient was admitted in ICU, and methylprednisolone, tacrolimus, piperacillin/tazobactam, vancomycin, ganciclovir, trimethoprim/sulfamethoxazole, and fluconazole were initiated. His vital signs were stable in ICU. His level of consciousness improved gradually, and after 72 hours, he was fully conscious; therefore, he had transferred to the posttransplant ward which some part of it was under construction without proper precautions. On postoperative day 4, his body temperature raised to 38.1°C. In addition to the fever, he presented agitation, disorientation, and loss of consciousness. Afterward, he experienced a right-sided hemiparesis and an episode of seizure presented with lateral gaze with tonic phase in upper and both of the lower limbs. He had a normal flexor plantar response. PRES (posterior reversible encephalopathy syndrome), brain ischemia, infectious diseases, and tacrolimus toxicity were suspected, so tacrolimus was discontinued and prednisolone and mycophenolate mofetil were initiated. His brain CT scan showed diffuse parenchymal hypodensity in left frontal and parietal lobes which suspected to a left-sided arterial stroke (Figure 3). Electroencephalography (EEG) showed multifocal sharp waves compatible with diffuse encephalopathy accompanied by predominantly right-sided hemiparesis. To get more information, brain MRI had done. Diffuse abnormal signal foci had seen in both hemispheres, and the largest one is in the left frontal, left temporoparietal, and right occipital regions along with peripheral vasogenic edema (Figure 4).

Table 1: Postoperation flow cytometry.

| CD  | 10 | Negative | CD20 | 6 (%) | CD64 | 5 (%) |
|-----|----|----------|------|-------|------|-------|
| CD117 | Negative | CD22 | 5 (%) | CD7 | 11 (%) |
| CD11b | 80 (%) | CD23 | 5a | Negative | CD71 | 3 (%) |
| CD13 | 55 (%) | CD3 | 11 (%) | CD8 | 4 (%) |
| CD14 | 3 (%) | CD33 | 8 (%) | HLA-DR | 11 (%) |
| CD15 | 78 (%) | CD34 | Negative | MPO | 79 (%) |
| CD19 | 6 (%) | CD4 | 6 (%) | TdT | Negative |
| CD2 | 11 (%) | CD5 | 10 (%) | Cyto CD79a | 9 (%) |
2). In further evaluations, the patient’s level of consciousness did not improve; therefore, he was transferred to ICU and underwent mechanical ventilation.

His level of electrolytes was balanced. Three days after transferring to ICU, due to prolonged fever and no response to antibiotic therapy, liposomal amphotericin B was added to his medication regimen. There was no proper clinical response to antimicrobial agents after 5 days of pharmacotherapy, so surgical drainage of brain lesions was performed. Abscess culture was positive for aspergillosis, and voriconazole was initiated, respectively. After about 20 days of ICU treatment, liposomal amphotericin B was added to the patient’s medication regimen. There was no proper clinical response to antimicrobial agents after 5 days of pharmacotherapy, so surgical drainage of brain lesions was performed. Abscess culture was positive for aspergillosis, and voriconazole was initiated, respectively. After about 20 days of ICU treatment.

3. Discussion

Aspergillus is an ubiquitous organism that involves various organs in the human body. Invasive aspergillosis involves lungs (56% of symptomatic cases), skin (5% of symptomatic cases), paranasal sinuses (5% of symptomatic cases), and central nervous system (6% of symptomatic cases). Invasive aspergillosis affects immunocompromised patients mostly (0.4% of pediatric admissions) [25]. The risk of invasive aspergillosis in patients with malignancies (74%), hematologic diseases (28%), and immunologic diseases (18%) is higher than similar immunosuppressive conditions such as the patients who had undergone bone marrow transplantation (15%) and solid organ transplantation (1%) [25]. Considering the presence of the organism in external auditory canals or respiratory tract, isolated CNS aspergillosis could cause due to direct invasion of the CNS or hematogenous spreading [26]. Aspergillus is an ubiquitous organism that could be found in the environment; therefore, one of the most important solutions to prevent invasive aspergillosis is controlling environmental factors. Installing high-efficiency particulate air filters (HEPA) makes a significant improvement in controlling nosocomial affliction [27, 28]. Triazoles (itraconazole, posaconazole, and voriconazole), echinocandins (caspofungin, micafungin, and anidulafungin), and polyenes (amphotericin B deoxycholate and liposomal amphotericin B) are used to prevent invasive aspergillosis (IA) as chemoprevention regimen. Although these prophylactic drugs have reduced invasive fungal infections, using them may cause other side effects, for example, using voriconazole has been associated with increasing zygomycosis in several studies [29–31]. Schwartz and colleagues treated patients with definite or possible central nervous system (CNS) aspergillosis with voriconazole which 35% of the patients responded completely or partially [32]. According to the study of Walsh and colleagues, voriconazole is recommended as first-line treatment and other antifungal agents such as other triazoles will be used in case the patient is intolerant or refractory to voriconazole [33]. Except for visual disturbances and skin reactions, other systemic side effects are more frequent in patients who received amphotericin B [31, 34]. CNS aspergillosis in this patient was treated by voriconazole, and surgical drainage also had done. Unfortunately, the brain lesion had destructive effects on the cerebral cortex and caused loss of consciousness and other neurological defects.

Conflicts of Interest

The authors declared no conflict of interest.

Authors’ Contributions

All authors contributed equally in preparing all parts of the research.

References

[1] M. Spada, S. Riva, G. Maggiore, D. Cintorino, and B. Gridelli, “Pediatric liver transplantation,” World Journal of Gastroenterology, vol. 15, no. 6, pp. 648–674, 2009.

[2] T. Berrocal, M. Parrón, A. Álvarez-Luque, C. Prieto, and M. Santamaría, “Pediatric liver transplantation: a pictorial essay of early and late complications,” Radiographics, vol. 26, no. 4, pp. 1187–1209, 2006.

[3] F. Romero and R. R. Razonable, "Infections in liver transplant recipients," World Journal of Hepatology, vol. 3, no. 4, pp. 83–92, 2011.
R. Patel and C. Paya, "Infections in solid-organ transplant recipients," Clinical Microbiology Reviews, vol. 10, no. 1, pp. 86–124, 1997.

D. Winston, C. Emmanouilides, and R. Busuttil, "Infections in liver transplant recipients," Clinical Infectious Diseases, vol. 21, no. 5, pp. 1077–1091, 1995.

N. Singh, M. Wagener, I. Marino, and T. Gayowski, "Infections in liver transplant recipients," Transplantation, vol. 36, no. 1, pp. 46–52, 2003.

J. Fortún, P. Martín-Dávila, S. Moreno et al., "Risk factors for invasive aspergillosis in liver transplant recipients," Liver Transplantation, vol. 8, no. 11, pp. 1065–1070, 2002.

S. Husain, B. Alexander, P. Munoz et al., "Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-aspergillus mycelial fungi," Clinical Infectious Diseases, vol. 37, no. 2, pp. 221–229, 2003.

T. Zaoutis, K. Heydon, J. H. Chu, T. J. Walsh, and W. J. Steinbach, "Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000," Pediatrics, vol. 117, no. 4, pp. e711–e716, 2006.

S. Enam, A. Shah, R. Jooma, S. Anwar, M. Shamim, and A. Siddiqui, "Craniofacial aspergillosis in immunocompetent hosts: surgical perspective," Neurology India, vol. 55, no. 3, p. 274, 2007.

J. Fishman, A. Michalek, B. Lipman, B. Segal, and P. McCarthy, "Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies," Infection Control and Hospital Epidemiology, vol. 23, no. 9, pp. 525–531, 2002.

J. Beyer, S. Schwartz, V. Heinemann, and W. Siegert, "Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients," Antimicrobial Agents and Chemotherapy, vol. 38, no. 5, pp. 911–917, 1994.

G. Siwek, K. Dodgson, M. de Margarida et al., "Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis," Clinical Infectious Diseases, vol. 39, no. 4, pp. 584–587, 2004.

S. Vigouroux, O. Morin, P. Moreau et al., "Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required," Clinical Infectious Diseases, vol. 40, no. 4, pp. e35–e37, 2005.

S. Magill, T. Chiller, and D. Warnock, "Evolving strategies in the management of aspergillosis," Expert Opinion on Pharmacotherapy, vol. 9, no. 2, pp. 193–209, 2008.

S. Schwartz, M. Ruhnke, P. Ribaud et al., "Improved outcome in central nervous system aspergillosis, using voriconazole treatment," Blood, vol. 106, no. 8, pp. 2641–2645, 2005.

T. Walsh, E. Anaissie, D. Denning et al., "Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America," Clinical Infectious Diseases, vol. 46, no. 3, pp. 327–360, 2008.

R. Herbrecht, D. Denning, T. Patterson et al., "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis," The New England Journal of Medicine, vol. 347, no. 6, pp. 408–415, 2002.